Immune Landscape of Pancreatic Cancer Development and Drug Resistance
Language: English
Published by Academic Pr, 2024
- Hardcover
- New

Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
US$ 265.94
Quantity: 1 available
Add to basketItem description from seller
330 pages. 9.25x7.50x0.75 inches. In Stock.
Seller Inventory # x-0443235236
- Title
- Immune Landscape of Pancreatic Cancer Development and Drug Resistance
- Author
- Farran, Batoul (Editor)/ Nagaraju, Ganji Purnachandra (Editor)
- Publisher
- Academic Pr
- Publication year
- 2024
- Condition
- Brand New
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 0443235236
- ISBN 13
- 9780443235238
- Item weight
- 0.73 kilograms
Immune Landscape of Pancreatic Cancer Development and Drug Resistance explores advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. With a strong focus on the development of therapeutic methods to improve the survival rates of pancreatic cancer, this book also shows the latest trends in immune targeted approaches for pancreatic cancer treatment. In 12 chapters, the book discusses our current understanding of PC development and its various mutational and immune features and explore some of the new immune-based therapies aimed at targeting pancreatic cancer.
This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of advances in immunotherapy in pancreatic cancer.
- Summarizes the potential combination strategies and latest clinical trials in pancreatic cancer
- Provides an in-depth overview of our current understanding of pancreatic cancer development, including its mutational and immune features
- Explores some of the new immune-based therapies aimed at targeting PC
- Shows pancreatic cancer progression and basic elements in tumor microenvironments and their role in PC progression, also covering immunotherapy strategies
"Synopsis" may belong to another edition of this title.
About the Author
Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | US$ 16.63 | US$ 39.92 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Shipping terms
Orders usually dispatched within two working days. Please note that at this time all domestic United Kingdom orders are sent by trackable UPS courier, we choose not to offer a lower cost alternative.